AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing — a BioCentury podcast

Nobel-winner Baker’s vision for what’s next in protein design. President Trump’s push for ‘most favored nation’ drug pricing

Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, Executive Director of Biopharma Intelligence Lauren Martz zeroes in on preclinical research supporting different degraders of SMARCA2 at this year’s American Association for Cancer Research (AACR) annual meeting.

BioCentury’s editors also discuss takeaways from Editor in Chief Simone Fishburn’s conversation with David Baker, the Nobel-prizewinning pioneer in protein design, about what’s next in his field.

In the latest from Washington, BioCentury’s Steve Usdin reports that pharmaceutical industry executives and lobbyists are in a state of alarm over President Donald Trump’s push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act’s “pill penalty” and FDA Commissioner Marty Makary’s decision to reject proposals to reorganize the agency. 

This episode was sponsored by Jeito Capital.